⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL931072 | 0.95 | — | — | |
| Phosphonic Acid SCHEMBL1191783 | 0.78 | — | — | |
| SCHEMBL10440719 | 0.74 | — | — | |
| SCHEMBL5914956 | 0.74 | — | — | |
| SCHEMBL363785 | 0.74 | — | — | |
| Water SCHEMBL9426678 | 0.70 | — | — | |
| SCHEMBL31088645 | 0.70 | — | — | |
| Hydrochloric Acid SCHEMBL3155415 | 0.70 | — | — | |
| SCHEMBL21351708 | 0.70 | — | — | |
| Ethane SCHEMBL9372881 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1031 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250008950-A1 | BIOCIDE COMPOSITIONS | BASF SE (DE) | 2025-01-09 | — | — | US | claimed |
| EP-4486924-A2 | NUCLEIC ACID CROSSLINKING REAGENTS AND USES THEREOF | Promega Corporation (US) | 2025-01-08 | — | — | EP | claimed |
| EP-4440307-A1 | BIOCIDE COMPOSITIONS | BASF SE (DE) | 2024-10-09 | — | — | EP | claimed |
| CN-115536610-B | Preparation method of vothixetine | 湖南省湘中制药有限公司 | 2024-01-23 | — | — | CN | claimed |
| US-20230366045-A1 | NUCLEIC ACID CROSSLINKING REAGENTS AND USES THEREOF | PROMEGA CORPORATION | 2023-11-16 | — | — | US | claimed |
| CN-116829154-A | Compounds for the prevention, treatment and diagnosis of thrombosis | 国家健康科学研究所 | 2023-09-29 | — | — | CN | claimed |
| WO-2023177976-A2 | NUCLEIC ACID CROSSLINKING REAGENTS AND USES THEREOF | PROMEGA CORPORATION (US) | 2023-09-21 | — | — | WO | claimed |
| CN-116601307-A | Nucleic acid modification reagent and use thereof | 普罗美加公司 | 2023-08-15 | — | — | CN | claimed |
| US-20230241057-A1 | COMPOUNDS FOR THE PREVENTION, TREATMENT AND DIAGNOSIS OF THROMBI | UNIVERSITE PARIS 13 PARIS-NORD (FR) | 2023-08-03 | — | — | US | claimed |
| EP-4208564-A1 | NUCLEIC ACID MODIFYING REAGENTS AND USES THEREOF | Promega Corporation (US) | 2023-07-12 | — | — | EP | claimed |
| US-20040052864-A1 | Restoring cancer-suppressing functions to neoplastic cells through DNA hypomethylation | SUPERGEN, INC. | 2004-03-18 | — | — | US | claimed |
| EP-1389127-A1 | COMPOSITIONS AND METHODS FOR REESTABLISHING GENE TRANSCRIPTION THROUGH INHIBITION OF DNA METHYLATION AND HISTONE DEACETYLASE | SuperGen, Inc. (US) | 2004-02-18 | — | — | EP | claimed |
| EP-1383379-A1 | RESTORATION OF CANCER-SUPPRESSING FUNCTIONS TO NEOPLASTIC CELLS THROUGH DNA HYPOMETHYLATION | SuperGen, Inc. (US) | 2004-01-28 | — | — | EP | claimed |
| US-20030191179-A1 | Methods for administration of paclitaxel | SUPERGEN, INC. | 2003-10-09 | — | — | US | claimed |
| EP-1276479-A2 | INHIBITION OF ABNORMAL CELL PROLIFERATION WITH CAMPTOTHECIN AND COMBINATIONS INCLUDING THE SAME | SuperGen, Inc. (US) | 2003-01-22 | — | — | EP | claimed |
| WO-2002085400-A1 | COMPOSITIONS AND METHODS FOR REESTABLISHING GENE TRANSCRIPTION THROUGH INHIBITION OF DNA METHYLATION AND HISTONE DEACETYLASE | SUPERGEN, INC. (US) | 2002-10-31 | — | — | WO | claimed |
| WO-2002067681-A1 | RESTORE CANCER-SUPPRESSING FUNCTIONS TO NEOPLASTIC CELLS THROUGH DNA HYPOMETHYLATION | SUPERGEN, INC. (US) | 2002-09-06 | — | — | WO | claimed |
| US-20020114809-A1 | Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation | ASTEX PHARMACEUTICALS, INC. | 2002-08-22 | — | — | US | claimed |
| US-20020111362-A1 | Inhibition of abnormal cell proliferation with camptothecin and combinations including the same | SUPERGEN, INC. | 2002-08-15 | — | — | US | claimed |
| WO-2001080843-A2 | INHIBITION OF ABNORMAL CELL PROLIFERATION WITH CAMPTOTHECIN AND COMBINATIONS INCLUDING THE SAME | SUPERGEN, INC. (US) | 2001-11-01 | — | — | WO | claimed |